Palaniswami Rathanaswami

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Amgen Fremont Inc., Amgen Inc.. Active years: 2007-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Palaniswami Rathanaswami. Retrieved from https://idiyas.com/inventor/palaniswami-rathanaswami

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 92.9

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 12.3

ph-index = 7

Forward Citations = 243(Granted Patents)

Company Filing History:

Years Active: 2007-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),

2. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2019-12-17),

3. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2018-11-06),

4. 9096672 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-08-04),

5. 9085624 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-21),

6. 9073998 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-07),

7. 9062113 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-06-23),

8. 8604174 - High affinity fully human monoclonal antibodies to interleukin-8 (2013-12-10),

9. 8101178 - Antibodies directed to tumor necrosis factor and uses thereof (2012-01-24),

10. 7994302 - Fully human monoclonal antibodies to IL-13 (2011-08-09),

11. 7736644 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2010-06-15),

12. 7628986 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2009-12-08),

13. 7585500 - Fully human monoclonal antibodies to IL-13 (2009-09-08),

14. 7285269 - Antibodies directed to tumor necrosis factor (2007-10-23),

Title: The Innovative Contributions of Palaniswami Rathanaswami

Introduction

Palaniswami Rathanaswami is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibodies. With a total of 14 patents to his name, Rathanaswami's work has the potential to impact therapeutic and diagnostic applications in medicine.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof." This invention focuses on novel antibodies that target deletion mutants of the epidermal growth factor receptor, specifically the type III deletion mutant known as EGFRvIII. The patent also encompasses human monoclonal antibodies directed against these deletion mutants, along with diagnostic and therapeutic formulations and immunoconjugates.

Career Highlights

Rathanaswami has had a distinguished career, working with prominent companies in the biotechnology sector. He has been associated with Amgen Fremont Inc. and Amgen Inc., where he has contributed to various innovative projects. His expertise in antibody development has positioned him as a key figure in his field.

Collaborations

Throughout his career, Rathanaswami has collaborated with several professionals, including Jaspal Singh Kang and Orit Foord. These collaborations have further enhanced his research and development efforts in biotechnology.

Conclusion

Palaniswami Rathanaswami's contributions to the field of biotechnology through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in medical diagnostics and therapeutics.

Profile summary based on public USPTO records.